Treatment Selection and Post-Menin Inhibitor Strategies

Dr. Arana Yi discusses menin inhibitor impact on traditional chemotherapy utilization in R/R NPM1-mutated disease. Current options favor targeted therapies versus salvage chemotherapy when available, with treatment selection considering prior therapy types, particularly venetoclax-based combination history. For patients considering transplant bridging with one to two chemotherapy cycles followed by transplant in otherwise fit patients without comorbidities, salvage chemotherapy remains reasonable. However, for elderly patients already exposed to venetoclax-based chemotherapy, menin inhibitors play predominant roles either as single agents or combinations.

Dr. Patel emphasizes prior venetoclax exposure as key decision-making factor. For patients fit for intensive chemotherapy who are venetoclax-naive, intensive chemotherapy plus venetoclax or hypomethylating agent (HMA) plus venetoclax approaches may be favored over menin inhibitors. However, patients with prior venetoclax exposure increasingly warrant menin inhibitor-based strategies over alternative options.

Post-menin inhibitor treatment represents challenging scenarios. Response duration in relapsed settings approximates 6 months according to clinical trials, often involving resistant mutations including MEN-1 configuration changes or cooperative pathway alterations. For patients remaining fit after menin inhibitor failure, clinical trial consideration becomes primary option. Sequential treatment efficacy with different menin inhibitors remains unclear regarding resistance potential differences. Published literature suggests some patients respond to venetoclax-based therapy re-treatment, particularly those retaining NPM1 mutations, with 40% to 50% response rates representing potential strategies for patients lacking targetable mutations or trial options.